Relevium Medical
Relevium Medical is a pharmaceutical company based in Ireland and the US, founded in 2019 as a spin-out from the University of Galway’s BioInnovate Programme, the only European affiliate of Stanford BioDesign. With support from Y Combinator, Enterprise Ireland and the European Innovation Council, the company is developing novel hydrogel-based therapeutics for chronic disorders, leveraging natural biopolymers and active agents for targeted, long-lasting treatment. Relevium has a world-class clinical advisory board and a growing pipeline including products for osteoarthritis, painful bladder, neurogenic bladder, & trauma wound infections. To date the company has secured a total of $8 million non-dilutive funding and private seed investment.
Industries
Nr. of Employees
small (1-50)
Relevium Medical
Unit 203B, Business Innovation Centre University of Galway Upper Newcastle Galway H91 NY52 Ireland
Relevium Medical is currently seeking investment
Relevium Medical is seeking a series-a investment in the range of 20m-50m
Products
Injectable hydrogel therapy for osteoarthritis (RM-010)
An injectable hydrogel designed for intra-articular administration to provide long-lasting pain relief, lubrication, and local delivery for moderate to severe knee osteoarthritis. Developed as a platform that can be extended to other joint conditions.
Hydrogel for bladder pain and interstitial cystitis (RM-020)
A hydrogel administered into the bladder to replace the damaged biopolymer lining and suppress sensitised pain nerves in interstitial cystitis.
Hydrogel for trauma wound infection with pain relief (RM-030)
A multimodal hydrogel for traumatic wounds, formulated with broad-spectrum antimicrobial properties and designed to provide pain relief and infection control.
Post-operative hydrogel pain relief treatment (RM-040)
A hydrogel-based therapy providing long-acting pain relief after surgery, intended to minimise the need for oral analgesics including opioids.
Injectable hydrogel therapy for osteoarthritis (RM-010)
An injectable hydrogel designed for intra-articular administration to provide long-lasting pain relief, lubrication, and local delivery for moderate to severe knee osteoarthritis. Developed as a platform that can be extended to other joint conditions.
Hydrogel for bladder pain and interstitial cystitis (RM-020)
A hydrogel administered into the bladder to replace the damaged biopolymer lining and suppress sensitised pain nerves in interstitial cystitis.
Hydrogel for trauma wound infection with pain relief (RM-030)
A multimodal hydrogel for traumatic wounds, formulated with broad-spectrum antimicrobial properties and designed to provide pain relief and infection control.
Post-operative hydrogel pain relief treatment (RM-040)
A hydrogel-based therapy providing long-acting pain relief after surgery, intended to minimise the need for oral analgesics including opioids.
Expertise Areas
- Chronic pain therapeutics
- Hydrogel drug development
- Pharmacological biopolymer integration
- Preclinical drug development
Key Technologies
- Hydrogel formulation
- Biopolymer therapeutics
- Intra-articular injection
- Cell-based disease modelling